


Silencing the black dog - Understanding cognitive side effects of electroconvulsive therapy
Joey Verdijk is a PhD student in the Department of Clinical Neurophysiology. (Co))Promotors are prof.dr. J. Hofmeijer from the Faculty of Science & Technology, prof.dr. G.A. van Wingen from the University of Amsterdam and dr. J.A. van Waarde from Rijnstate Hospital.

Major depressive disorder is one of the most prevalent and disabling disorders. Electroconvulsive therapy (ECT) is the most effective treatment, but stigma, insufficient knowledge among clinicians, and concerns about cognitive side effects contribute to its underuse, which further study may help reduce. This dissertation focuses on the side effects of ECT, particularly postictal agitation and cognitive impairments.
Severe postictal agitation occurred in 25% of patients, predominantly during the first five sessions, but did not influence treatment efficacy. Flumazenil administered prior to the ECT stimulus was associated with more postictal agitation. In contrast to earlier evidence, our randomized cross-over trial found no effect of acetaminophen or nimodipine on postictal agitation. Of medications to prevent cognitive side effects, memantine and liothyronine showed the greatest promise for attenuating cognitive decline.
Using multiple MRI modalities in our trial, we found that within-network strength of the default mode network normalized in ECT patients. Acute brain-wide increases in white matter diffusivity were associated with postictal agitation, but integrity was only transiently disrupted. Increased diffusivity persisted at three months and co-occurred with sustained clinical improvement. Deep brain volume increased acutely after an ECT session but normalized within three months after the course.
In this dissertation we hypothesize that ECT electrically induces subtle cytotoxic edema—manifesting as transient postictal agitation—as well as local neuroinflammation and microglial activation—likely increasing white matter diffusivity—that in turn induce neuroplasticity and recovery from depression. Medication protecting against microglial over-activation, such as memantine, may reduce cognitive side effects of ECT by modulating the neuroinflammatory cascade and deserves further study.